{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:58:32Z","timestamp":1792429112984,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007625","name":"cure alzheimer's fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"jpb foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"national institute of neurological disorders and stroke","doi-asserted-by":"publisher","award":["NS090932"],"award-info":[{"award-number":["NS090932"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"national institute on aging","doi-asserted-by":"publisher","award":["AG047644"],"award-info":[{"award-number":["AG047644"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-\u03b2 (A\u03b2) peptide into amyloid plaques. The apolipoprotein E (<jats:italic>APOE<\/jats:italic>) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of A\u03b2 in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of A\u03b2 plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We utilized <jats:italic>APOE<\/jats:italic> knock-in mice capable of having <jats:italic>APOE<\/jats:italic> selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP\/PS1-21 mouse model of amyloidosis. We analyzed the changes to A\u03b2 plaque levels and assessed the impact on cellular responses to A\u03b2 plaques when astrocytic <jats:italic>APOE<\/jats:italic> is removed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in A\u03b2 plaque deposition and less compact plaques. While overall Iba1<jats:sup>+<\/jats:sup> microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around\u00a0remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of A\u03b2 plaques as well as on\u00a0certain A\u03b2-associated downstream effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13024-022-00516-0","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T19:02:22Z","timestamp":1643828542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A\u03b2 accumulation and plaque-related pathology in a mouse model of amyloidosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Thomas E.","family":"Mahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"516_CR1","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17:327\u2013406. https:\/\/pubmed.ncbi.nlm.nih.gov\/33756057\/.","DOI":"10.1002\/alz.12328"},{"key":"516_CR2","volume-title":"Numbers of people with dementia around the world","author":"M Guerchet","year":"2020","unstructured":"International AD, Guerchet M, Prince M. Numbers of people with dementia around the world. 2020."},{"key":"516_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006312.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA - J Am Med Assoc. 2015;313:1924\u201338.","journal-title":"JAMA - J Am Med Assoc"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science."},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"516_CR8","doi-asserted-by":"crossref","unstructured":"Tosun D, Veitch D, Aisen P, Jack CR, Jagust WJ, Petersen RC, et al. Detection of \u03b2-amyloid positivity in Alzheimer\u2019s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021;3:fcab008.","DOI":"10.1093\/braincomms\/fcab008"},{"key":"516_CR9","doi-asserted-by":"crossref","unstructured":"Jack CR, Holtzman DM. Biomarker modeling of alzheimer\u2019s disease. Neuron. 2013;80:1347\u201358.","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163\u20136.","journal-title":"Brain Res"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0304-3940(92)90444-C","volume":"135","author":"T Wisniewski","year":"1992","unstructured":"Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235\u20138.","journal-title":"Neurosci Lett"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med. 2011;3:89ra57.","journal-title":"Sci Transl Med"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8","volume":"47","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer\u2019s disease model. Ann Neurol. 2000;47:739\u201347.","journal-title":"Ann Neurol"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 1999;96:15233\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1523\/JNEUROSCI.3773-11.2011","volume":"31","author":"J Kim","year":"2011","unstructured":"Kim J, Jiang H, Park S, Eltorai AEM, Stewart FR, Yoon H, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-\u03b2 amyloidosis. J Neurosci. 2011;31:18007\u201312.","journal-title":"J Neurosci"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","volume":"11","author":"G William Rebeck","year":"1993","unstructured":"William Rebeck G, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer\u2019s disease: allelic variation and receptor interactions. Neuron. 1993;11:575\u201380.","journal-title":"Neuron."},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nn.4018","volume":"18","author":"ES Musiek","year":"2015","unstructured":"Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and \u201cwingmen.\u201d. Nat Neurosci. 2015;18:800\u20136.","journal-title":"Nat Neurosci"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron. 2009;63:287\u2013303.","journal-title":"Neuron."},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2000;97:2892\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/nbdi.2002.0483","volume":"9","author":"AM Fagan","year":"2002","unstructured":"Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A\u03b2 metabolism before and after plaque formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2002;9:305\u201318.","journal-title":"Neurobiol Dis"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1523\/JNEUROSCI.0033-12.2012","volume":"32","author":"N Bien-Ly","year":"2012","unstructured":"Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent A\u03b2 accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32:4803\u201311.","journal-title":"J Neurosci"},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501\u201318.","journal-title":"Nat Rev Neurol"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in A\u03b2 accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774\u201386.","journal-title":"J Biol Chem"},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"1047 LP","DOI":"10.1084\/jem.20171265","volume":"215","author":"JD Ulrich","year":"2018","unstructured":"Ulrich JD, Ulland TK, Mahan TE, Nystr\u00f6m S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047 LP\u20131058.","journal-title":"J Exp Med"},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s004010000263","volume":"100","author":"MC Irizarry","year":"2000","unstructured":"Irizarry MC, Cheung BS, Rebeck GW, Paul SM, Bales KR, Hyman BT. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid \u03b2-peptide deposition in homozygous APP V717F transgenic mice. Acta Neuropathol. 2000;100:451\u20138.","journal-title":"Acta Neuropathol"},{"key":"516_CR26","doi-asserted-by":"crossref","unstructured":"Huynh T-PV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, et al. Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron. 2017;96:1013\u201323.e4.","DOI":"10.1016\/j.neuron.2017.11.014"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"CC Liu","year":"2017","unstructured":"Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96:1024\u20131032.e3.","journal-title":"Neuron."},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566\u2013581.e9.","journal-title":"Immunity."},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276\u20131290.e17.","journal-title":"Cell."},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ana.24304","volume":"77","author":"O Butovsky","year":"2015","unstructured":"Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77:75\u201399.","journal-title":"Ann Neurol"},{"key":"516_CR31","doi-asserted-by":"crossref","unstructured":"Pimenova AA, Marcora E, Goate AM. A tale of two genes: microglial Apoe and Trem2. Immunity. 2017;47:398\u2013400.","DOI":"10.1016\/j.immuni.2017.08.015"},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523\u20137.","journal-title":"Nature."},{"key":"516_CR33","doi-asserted-by":"crossref","unstructured":"Huynh TPV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, et al. Lack of hepatic apoE does not influence early A\u03b2 deposition: observations from a new APOE knock-in model. Mol Neurodegener. 2019;14:37.","DOI":"10.1186\/s13024-019-0337-1"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","volume":"22","author":"S Parhizkar","year":"2019","unstructured":"Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22:191\u2013204.","journal-title":"Nat Neurosci"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neurobiolaging.2017.03.002","volume":"54","author":"J y Zheng","year":"2017","unstructured":"Zheng J y, Sun J, Ji C m, Shen L, Chen Z j, Xie P, et al. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer\u2019s disease (APP\/PS1) mice by inhibiting TGF-\u03b2\/Smad2\/STAT3 signaling. Neurobiol Aging. 2017;54:112\u201332.","journal-title":"Neurobiol Aging"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940\u20136.","journal-title":"EMBO Rep"},{"key":"516_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","volume":"64","author":"J Kim","year":"2009","unstructured":"Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632\u201344.","journal-title":"Neuron."},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nn.2801","volume":"14","author":"AW Bero","year":"2011","unstructured":"Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-\u03b2 deposition. Nat Neurosci. 2011;14:750\u20136.","journal-title":"Nat Neurosci"},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40478-015-0250-y","volume":"3","author":"F Liao","year":"2015","unstructured":"Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, et al. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol Commun. 2015;3:70.","journal-title":"Acta Neuropathol Commun"},{"key":"516_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jneumeth.2010.12.025","volume":"196","author":"KL Youmans","year":"2011","unstructured":"Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, et al. Amyloid-\u03b242 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J Neurosci Methods. 2011;196:51.","journal-title":"J Neurosci Methods"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"43243","DOI":"10.1074\/jbc.M508781200","volume":"280","author":"V Hirsch-Reinshagen","year":"2005","unstructured":"Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain J-F, Naus KE, McIsaac SA, et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243\u201356.","journal-title":"J Biol Chem"},{"key":"516_CR42","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141\u20131154.e7.","journal-title":"Neuron."},{"key":"516_CR43","doi-asserted-by":"crossref","unstructured":"Perez-Nievas BG, Serrano-Pozo A. Deciphering the astrocyte reaction in Alzheimer\u2019s disease. Front Aging Neurosci. 2018;10:114.","DOI":"10.3389\/fnagi.2018.00114"},{"key":"516_CR44","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019;22:1217\u201322.","journal-title":"Nat Neurosci"},{"key":"516_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","volume":"132","author":"KR Sadleir","year":"2016","unstructured":"Sadleir KR, Kandalepas PC, Buggia-Pr\u00e9vot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer\u2019s disease. Acta Neuropathol. 2016;132:235\u201356.","journal-title":"Acta Neuropathol"},{"key":"516_CR46","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41380-019-0396-2","volume":"24","author":"MG Sharoar","year":"2019","unstructured":"Sharoar MG, Hu X, Ma XM, Zhu X, Yan R. Sequential formation of different layers of dystrophic neurites in Alzheimer\u2019s brains. Mol Psychiatry. 2019;24:1369\u201382.","journal-title":"Mol Psychiatry"},{"key":"516_CR47","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/sj.emboj.7601707","volume":"26","author":"X Hu","year":"2007","unstructured":"Hu X, Shi Q, Zhou X, He W, Yi H, Yin X, et al. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. EMBO J. 2007;26:2755\u201367.","journal-title":"EMBO J"},{"key":"516_CR48","doi-asserted-by":"crossref","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339.","DOI":"10.1016\/j.cell.2019.09.001"},{"key":"516_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/glia.22619","volume":"62","author":"SD Mulder","year":"2014","unstructured":"Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia. 2014;62:493\u2013503.","journal-title":"Glia."},{"key":"516_CR50","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/glia.21004","volume":"58","author":"HM Nielsen","year":"2010","unstructured":"Nielsen HM, Mulder SD, Beli\u00ebn JAM, Musters RJP, Eikelenboom P, Veerhuis R. Astrocytic A\u03b21-42 uptake is determined by A\u03b2-aggregation state and the presence of amyloid-associated proteins. Glia. 2010;58:1235\u201346.","journal-title":"Glia."},{"key":"516_CR51","doi-asserted-by":"crossref","unstructured":"Martiskainen H, Haapasalo A, Kurkinen KM, Pihlajam\u00e4ki J, Soininen H, Hiltunen M. Targeting ApoE4\/ApoE receptor LRP1 in Alzheimer\u2019s disease. Expert Opin Ther Targets. 2013;17:781\u201394.","DOI":"10.1517\/14728222.2013.789862"},{"key":"516_CR52","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1021\/bi5008172","volume":"53","author":"K Garai","year":"2014","unstructured":"Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-\u03b2 alters the kinetics of amyloid aggregation. Biochemistry. 2014;53:6323\u201331.","journal-title":"Biochemistry."},{"key":"516_CR53","doi-asserted-by":"publisher","first-page":"10602","DOI":"10.1074\/jbc.271.18.10602","volume":"271","author":"AA Golabek","year":"1996","unstructured":"Golabek AA, Soto C, Vogel T, Wisniewski T. The interaction between apolipoprotein E and Alzheimer\u2019s amyloid \u03b2-peptide is dependent on \u03b2-peptide conformation. J Biol Chem. 1996;271:10602\u20136.","journal-title":"J Biol Chem"},{"key":"516_CR54","first-page":"1030","volume":"145","author":"T Wisniewski","year":"1994","unstructured":"Wisniewski T, Casta\u00f1o EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer\u2019s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030\u20135.","journal-title":"Am J Pathol"},{"issue":"Pt 2","key":"516_CR55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1042\/bj3060599","volume":"306","author":"EM Castano","year":"1995","unstructured":"Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, et al. Fibrillogenesis in Alzheimer\u2019s disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306(Pt 2):599\u2013604.","journal-title":"Biochem J"},{"key":"516_CR56","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/febs.15075","volume":"287","author":"T Islam","year":"2020","unstructured":"Islam T, Gharibyan AL, Golchin SA, Pettersson N, Br\u00e4nnstr\u00f6m K, Hedberg I, et al. Apolipoprotein E impairs amyloid-\u03b2 fibril elongation and maturation. FEBS J. 2020;287:1208\u201319.","journal-title":"FEBS J"},{"key":"516_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/372092a0","volume":"372","author":"J Ma","year":"1994","unstructured":"Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins \u03b11-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer \u03b2-protein into filaments. Nature. 1994;372:92\u20134.","journal-title":"Nature."},{"key":"516_CR58","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/glia.23974","volume":"69","author":"MF Lanfranco","year":"2021","unstructured":"Lanfranco MF, Sepulveda J, Kopetsky G, Rebeck GW. Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation. Glia. 2021;69:1478\u201393.","journal-title":"Glia."},{"key":"516_CR59","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.nbd.2003.08.009","volume":"14","author":"J Wang","year":"2003","unstructured":"Wang J, Tanila H, Puoliv\u00e4li J, Kadish I, Van Groen T. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis. 2003;14:318\u201327.","journal-title":"Neurobiol Dis"},{"key":"516_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/0023677215615269","volume":"50","author":"X Li","year":"2016","unstructured":"Li X, Feng Y, Wu W, Zhao J, Fu C, Li Y, et al. Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer\u2019s disease. Lab Anim. 2016;50:275\u201385.","journal-title":"Lab Anim"},{"key":"516_CR61","first-page":"438","volume":"10","author":"EE Sundermann","year":"2018","unstructured":"Sundermann EE, Tran M, Maki PM, Bondi MW. Sex differences in the association between apolipoprotein E \u03b54 allele and Alzheimer\u2019s disease markers. Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit. 2018;10:438.","journal-title":"Alzheimer\u2019s Dement Diagnosis, Assess Dis Monit"},{"key":"516_CR62","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/ene.13987","volume":"26","author":"S Shen","year":"2019","unstructured":"Shen S, Zhou W, Chen X, Zhang J. Sex differences in the association of APOE \u03b54 genotype with longitudinal hippocampal atrophy in cognitively normal older people. Eur J Neurol. 2019;26:1362\u20139.","journal-title":"Eur J Neurol"},{"key":"516_CR63","doi-asserted-by":"crossref","unstructured":"Huang YWA, Zhou B, Wernig M, S\u00fcdhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A\u03b2 secretion. Cell. 2017;168 undefined-undefined.","DOI":"10.1016\/j.cell.2016.12.044"},{"key":"516_CR64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1177\/002215540004800906","volume":"48","author":"SD Styren","year":"2000","unstructured":"Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer\u2019s disease pathology. J Histochem Cytochem. 2000;48:1223\u201332.","journal-title":"J Histochem Cytochem"},{"key":"516_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/glia.24105","volume":"70","author":"CM Henningfield","year":"2022","unstructured":"Henningfield CM, Arreola MA, Soni N, Spangenberg EE, Green KN. Microglia-specific ApoE knock-out does not alter Alzheimer\u2019s disease plaque pathogenesis or gene expression. Glia. 2022;70:287\u2013302.","journal-title":"Glia."},{"key":"516_CR66","doi-asserted-by":"crossref","unstructured":"Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667\u201375.","DOI":"10.1084\/jem.20151948"},{"key":"516_CR67","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A\u03b242 hotspots around plaques. Nat Commun. 2015;6:6176.","journal-title":"Nat Commun"},{"key":"516_CR68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neurobiolaging.2017.03.021","volume":"55","author":"Z Yin","year":"2017","unstructured":"Yin Z, Raj D, Saiepour N, Van Dam D, Brouwer N, Holtman IR, et al. Immune hyperreactivity of A\u03b2 plaque-associated microglia in Alzheimer\u2019s disease. Neurobiol Aging. 2017;55:115\u201322.","journal-title":"Neurobiol Aging"},{"key":"516_CR69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fnagi.2015.00124","volume":"7","author":"R von Bernhardi","year":"2015","unstructured":"von Bernhardi R, Eugen\u00edn-von Bernhardi L, Eugen\u00edn J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 2015;7:124.","journal-title":"Front Aging Neurosci"},{"key":"516_CR70","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.conb.2015.10.004","volume":"36","author":"C Villegas-Llerena","year":"2016","unstructured":"Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer\u2019s disease. Curr Opin Neurobiol. 2016;36:74\u201381.","journal-title":"Curr Opin Neurobiol"},{"key":"516_CR71","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1038\/s41467-021-23762-0","volume":"12","author":"NF Fitz","year":"2021","unstructured":"Fitz NF, Nam KN, Wolfe CM, Letronne F, Playso BE, Iordanova BE, et al. Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer\u2019s disease. Nat Commun. 2021;12:3416.","journal-title":"Nat Commun"},{"key":"516_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2019.00014","volume":"10","author":"CG Fernandez","year":"2019","unstructured":"Fernandez CG, Hamby ME, McReynolds ML, Ray WJ. The role of apoE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer\u2019s disease. Front Aging Neurosci. 2019;10:14.","journal-title":"Front Aging Neurosci"},{"key":"516_CR73","doi-asserted-by":"publisher","first-page":"26033","DOI":"10.1074\/jbc.M115.677286","volume":"290","author":"CC Bailey","year":"2015","unstructured":"Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem. 2015;290:26033\u201342.","journal-title":"J Biol Chem"},{"key":"516_CR74","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328\u201340.","journal-title":"Neuron."},{"key":"516_CR75","doi-asserted-by":"publisher","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","volume":"290","author":"Y Atagi","year":"2015","unstructured":"Atagi Y, Liu C-C, Painter MM, Chen X-F, Verbeeck C, Zheng H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290:26043\u201350.","journal-title":"J Biol Chem"},{"key":"516_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","volume":"24","author":"C Escartin","year":"2021","unstructured":"Escartin C, Galea E, Lakatos A, O\u2019Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24:312\u201325.","journal-title":"Nat Neurosci"},{"key":"516_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0306-4522(01)00169-5","volume":"105","author":"T Dickson","year":"2001","unstructured":"Dickson T, Vickers J. The morphological phenotype of \u03b2-amyloid plaques and associated neuritic changes in Alzheimer\u2019s disease. Neuroscience. 2001;105:99\u2013107.","journal-title":"Neuroscience."},{"key":"516_CR78","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41590-021-00913-5","volume":"22","author":"Y Huang","year":"2021","unstructured":"Huang Y, Happonen KE, Burrola PG, O\u2019Connor C, Hah N, Huang L, et al. Microglia use TAM receptors to detect and engulf amyloid \u03b2 plaques. Nat Immunol. 2021;22:586\u201394.","journal-title":"Nat Immunol"},{"key":"516_CR79","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.neuron.2016.05.003","volume":"90","author":"P Yuan","year":"2016","unstructured":"Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, et al. TREM2 Haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724\u201339.","journal-title":"Neuron."},{"key":"516_CR80","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.neuron.2021.01.005","volume":"109","author":"X Li","year":"2021","unstructured":"Li X, Zhang J, Li D, He C, He K, Xue T, et al. Astrocytic ApoE reprograms neuronal cholesterol metabolism and histone-acetylation-mediated memory. Neuron. 2021;109:957\u2013970.e8.","journal-title":"Neuron."},{"key":"516_CR81","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6:254\u201364.","journal-title":"Protein Cell"},{"key":"516_CR82","doi-asserted-by":"crossref","unstructured":"Yu T-S, Tensaouti Y, Stephanz EP, Chintamen S, Rafikian EE, Yang M, Kernie SG. Astrocytic ApoE underlies maturation of hippocampal neurons and cognitive recovery after traumatic brain injury in mice. Commun Biol. 2021;4:1303.","DOI":"10.1038\/s42003-021-02841-4"},{"key":"516_CR83","doi-asserted-by":"crossref","unstructured":"Laskowitz DT, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab. 1998;18:465\u201371.","DOI":"10.1097\/00004647-199805000-00001"},{"key":"516_CR84","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","volume":"26","author":"J Zhao","year":"2017","unstructured":"Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, et al. APOE \u03f54\/\u03f54 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26:2690\u2013700.","journal-title":"Hum Mol Genet"},{"key":"516_CR85","doi-asserted-by":"publisher","first-page":"38408","DOI":"10.1074\/jbc.M112.415505","volume":"287","author":"B Hitt","year":"2012","unstructured":"Hitt B, Riordan SM, Kukreja L, Eimer WA, Rajapaksha TW, Vassar R. \u03b2-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem. 2012;287:38408\u201325.","journal-title":"J Biol Chem"},{"key":"516_CR86","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00401-013-1152-3","volume":"126","author":"PC Kandalepas","year":"2013","unstructured":"Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R. The Alzheimer\u2019s \u03b2-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol. 2013;126:329.","journal-title":"Acta Neuropathol"},{"key":"516_CR87","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1523\/JNEUROSCI.2643-17.2018","volume":"38","author":"S Hartmann","year":"2018","unstructured":"Hartmann S, Zheng F, Kyncl MC, Karch S, Voelkl K, Zott B, et al. \u03b2-Secretase BACE1 promotes surface expression and function of Kv3.4 at hippocampal mossy Fiber synapses. J Neurosci. 2018;38:3480\u201394.","journal-title":"J Neurosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00516-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:05:22Z","timestamp":1666703122000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00516-0","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures and experiments were performed under guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at Washington University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved of the manuscript and agreed with its submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neuroscience. All other authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}